Hasnyálmirigyrák: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• KRAS 67
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• FGFR 1
• HSP90 0
• CTNNB1 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• NTRK 1
• RET 0

6+ intézményből 6, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Ciprus· EU contribution 1 500 000 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Ausztria· EU contribution 230 185 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 4 366 500 EUR· until 2030. dec.· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 2 497 125 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Out-of-Distribution-aware Reasoning Agents for Clinical Learning and Exploration (ORACLE)

  Friedrich-Alexander-Universitaet Erlangen-Nuernberg· Erlangen, Németország· EU contribution 150 000 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pancreatic juice-based Early Cancer Identification using Specific Epigenetics and (Glyco-)Proteomics – Advanced Next-generation Characterisation (PRECISE-PANC)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 2 499 998 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-EIC

  Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)

  Basinnov Life Sciences Unipessoal Lda· Lisboa, Portugália· EU contribution 2 827 529 EUR· until 2029. szept.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  AI-Driven Drug Discovery: Pancreatic Cancer Resistance via ENT1 Differential Conformation Tracking (PREDiCT-AI)

  The University of Sheffield· Sheffield, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.· 2 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALISED NUTRITIONAL CARE FOR OLDER PATIENTS WITH LEUKAEMIA OR PANCREATIC CANCER – A PRAGMATIC IMPLEMENTATION TRIAL TO IMPROVE QUALITY OF LIFE (NutriCa65)

  Universitetet I Bergen· Bergen, Norvégia· EU contribution 5 296 543 EUR· until 2030. aug.· 9 countries

10 of 58 running projects, newest first. Listed amounts together: 177,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

  NCT06544655· Bristol-Myers Squibb· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 300
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• Primer exchange reaction-based dual-signal amplified nano-flow cytometry and fluorescence analysis of MUC1- positive exosomes.

  Talanta, 2026. júl.

• High-quality acinar cell isolation enables single-cell analysis of healthy and injured pancreas.

  Cell Rep Methods, 2026. ápr.

• Assessment of NK cell cytotoxicity induced by IL-15 based immunotherapy against cancer cells.

  Methods Cell Biol, 2026. ápr.

• Single-cell RNA sequencing and high-dimensional flow cytometry reveal distinct peripheral immune landscapes of type 1 autoimmune pancreatitis and pancreatic ductal adenocarcinoma.

  Clin Transl Med, 2026. ápr.

• Protocol for analyzing immune cell infiltration in 3D pancreatic heterotypic spheroids composed of tumor cells and cancer-associated fibroblasts.

  STAR Protoc, 2026. febr.

• Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subsets in pancreatic ductal adenocarcinoma.

  Clin Immunol, 2026. jan.

• Single-Cell RNA Sequencing of Pancreatic Circulating Tumor Cells.

  Methods Mol Biol, 2026. jan.

• Bone Marrow Metastasis from a Pancreatic Neuroendocrine Tumor: Morphologic Mimicry of Acute Leukemia.

  Clin Lab, 2025. dec.

• Investigation of the synergistic effect of metformin and FX11 on PANC-1 cell lines.

  Biol Res, 2025. márc.

• Classical and atypical resistance of cancer cells as a target for resveratrol.

  Oncol Rep, 2016. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.